SCHEMBL4677650

SCHEMBL4677650

O=C(C=C(O)c1nc[nH]n1)c1ccoc1Cc1ccccc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.35
GAA P10253 2/20 0.33
CYP2C19 P33261 2/20 0.33
USP2 O75604 2/20 0.33
CYP1A1 P04798 1/20 0.33
ABCB1 P08183 1/20 0.33
CYP1B1 Q16678 1/20 0.33
GPR55 Q9Y2T6 1/20 0.33
MEN1 O00255 1/20 0.33
POLB P06746 1/20 0.33
KMT2A Q03164 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
ALDH1A1 P00352 3/20 0.33
HPGD P15428 1/20 0.33
GFER P55789 1/20 0.33
NPC1 O15118 1/20 0.32
MAPT P10636 1/20 0.32
RAB9A P51151 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4673027 0.91 TP53 (0.34) TP53NPC1RAB9A
SCHEMBL4671571 0.91 TP53 (0.44) TP53GAACYP1A1ABCB1CYP1B1
SCHEMBL4675254 0.90 KDM4C (0.34) TP53GAAMAPTKDM4AKDM5A
SCHEMBL4672236 0.90 TP53 (0.33) TP53
SCHEMBL4671946 0.90 TP53 (0.33) TP53POLBKMT2AALDH1A1HPGD
SCHEMBL5899392 0.90 HCAR2 (0.39) TP53POLBALDH1A1MAPTKDM5A
SCHEMBL4679843 0.90 SMN1; SMN2 (0.41) MEN1KMT2ACYP3A4ALDH1A1NPC1
SCHEMBL4673482 0.88 KMT2A (0.36) TP53CYP1A1ABCB1CYP1B1MEN1
SCHEMBL4673937 0.88 TP53 (0.39) TP53CYP1A1ABCB1CYP1B1POLB
SCHEMBL4676408 0.88 KDM4C (0.43) NPC1RAB9ANPSR1KDM4CKDM5B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 TP53 999/4885GAA 1884/4885CYP2C19 53/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.